EP1327628B1 - Lipidisation de molecules hydrophiles - Google Patents
Lipidisation de molecules hydrophiles Download PDFInfo
- Publication number
- EP1327628B1 EP1327628B1 EP03006780A EP03006780A EP1327628B1 EP 1327628 B1 EP1327628 B1 EP 1327628B1 EP 03006780 A EP03006780 A EP 03006780A EP 03006780 A EP03006780 A EP 03006780A EP 1327628 B1 EP1327628 B1 EP 1327628B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- bbi
- lipid
- cells
- bbisspal
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/56—Protease inhibitors from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/70—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/70—Sulfur atoms
- C07D213/71—Sulfur atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/048—Pyridine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0065—Oxidoreductases (1.) acting on hydrogen peroxide as acceptor (1.11)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3515—Lipophilic moiety, e.g. cholesterol
Definitions
- the present invention relates generally to the fields of biology and medicine. More particularly, the present invention relates to methods and compositions useful in increasing in mammals the absorption and retention of hydrophilic molecules, in particular peptides and proteins.
- Alternative routes of protein and peptide delivery may include the buccal, nasal, oral, pulmonary, rectal and ocular routes. Without exception, these routes are less effective than the parenteral routes of administration. However, these routes of protein and peptide delivery are still far more attractive than the parenteral routes because they offer convenience and control to the patients. The oral route is particularly attractive because it is the most convenient and patient-compliant.
- Mucosal barriers which separate the inside of the body from the outside (e.g. GI, ocular, pulmonary, rectal and nasal mucosa), comprise a layer of tightly joined cell monolayers which strictly regulates the transport of molecules. Individual cells in barriers are joined by tight junctions which regulate entry into the intercellular space. Hence, the mucosa is at the first level a physical barrier, transport through which depends on either the transcellular or the paracellular pathways [ Lee, V.H.L. (1988) CRC. Critical Rev. Ther. Drug Delivery Sys. 5, 69-97 ].
- the cell membrane of mucosal barriers is a hydrophobic lipid bilayer which has no affinity for hydrophilic, charged macromolecules like proteins and peptides.
- mucosal cells may secrete mucin which can act as a barrier to the transport of many macromolecules [ Edwards, P. (1978) British Med. Bull. 34, 55-56 ]. Therefore, unless specific transport mechanisms exist for protein and peptide, their inherent transport across mucosal barriers is almost negligible.
- vesicles Once the carrier is bound to the cell surface, it is taken up into vesicles. These vesicles then become processed stepwise and can be routed to several pathways.
- One pathway is the recycling of the vesicle back to the membrane from which it was invaginated.
- Another pathway which is destructive to the conjugate, is the fusion with lysosomes.
- An alternative pathway, and one which leads to the transcytosis of the conjugate, is the fusion of the vesicle with the membrane opposite to the side from which it was derived.
- Also disclosed are methods for increasing the absorption or prolonging blood and tissue retention in a mammal of a sulfhydryl-containing compound of the general formula PSH are provided, in which a conjugate of general formula VI is formed from the sulfhydryl-containing compound and the conjugate is then administered to the mammal (for example, in an aqueous solution or an oral dosage unit).
- Confluent cell monolayers 2 to 3 weeks old, and having a TEER value of approximately 500 ⁇ cm 2 , were first incubated with Dulbecco's MEM containing 1 % of FBS for 30 min at 37°C. Subsequently, the incubation medium was removed, and the 125 I-BBI (10 ⁇ g/ml) conjugates in 1.5 ml of the medium was added to the apical chamber of the transwells. To the basal chamber, 2.5 ml of the medium was added and the transwells were incubated at 37°C. At predetermined times, the entire basal chamber medium (2.5 ml) from each transwell was removed and counted for radioactivity using a gamma counter.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Pyridine Compounds (AREA)
- Saccharide Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Manufacturing Of Micro-Capsules (AREA)
Claims (6)
- Utilisation d'un fragment contenant un lipide dans la fabrication d'un composé pour la délivrance d'un composé contenant un groupe sulfhydryle à des cellules de mammifère,
dans laquelle ledit fragment contenant un lipide est un composé de formule générale V ;
A-S-S-CH2-CR1(NHCOR2)C(=O)R3 V
dans laquelle ledit composé pour la délivrance d'un composé contenant un groupe sulfhydryle a une formule générale VI ;
P-S-S-CH2-C (COR3) R1NHC (=O) R2 VI
dans laquelle A est un résidu d'activation aromatique ; P est un fragment issu du composé contenant un groupe sulfhydryle de formule générale PSH choisi dans le groupe constitué par des peptides, des protéines et des oligonucléotides ; R1 est hydrogène ou aryle ; R2 est un fragment contenant un lipide, comprenant un groupe lipidique ; et R3 est -OH, un fragment contenant un lipide, comprenant un groupe lipidique ou une chaîne d'acides aminés comprenant un ou deux acides aminés se terminant en -CO2H ou -COR2. - Utilisation selon la revendication 1, dans laquelle A est 2-pyridyle ou 4-nitrophényle.
- Utilisation selon les revendications 1-2, dans laquelle R1 est hydrogène, R2 est un groupe lipidique et R3 est -OH.
- Utilisation selon les revendications 1-2, dans laquelle R1 est hydrogène, R2 est -CH2CH2CH(NH2)CO2H ou -CH2CH2CH (NHCO-lipide) CO-lipide et R3 est -NHCH2CO2H ou -NHCH2CO-lipide où au moins l'un de R2 et R3 comprend un groupe lipidique.
- Utilisation selon les revendications 1-2, dans laquelle ledit groupe lipidique est un substituant hydrophobe comprenant 4 à 26 atomes de carbone.
- Utilisation selon les revendications 1-2, dans laquelle ledit groupe lipidique est un substituant hydrophobe comprenant 5 à 19 atomes de carbone.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US349717 | 1989-05-09 | ||
US34971795A | 1995-01-25 | 1995-01-25 | |
US08/524,362 US5907030A (en) | 1995-01-25 | 1995-09-05 | Method and compositions for lipidization of hydrophilic molecules |
US524362 | 1995-09-05 | ||
EP96903690A EP0820285B1 (fr) | 1995-01-25 | 1996-01-25 | Procedes et compositions de lipidisation de molecules hydrophiles |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP96903690A Division EP0820285B1 (fr) | 1995-01-25 | 1996-01-25 | Procedes et compositions de lipidisation de molecules hydrophiles |
EP96903690.4 Division | 1996-08-01 |
Publications (3)
Publication Number | Publication Date |
---|---|
EP1327628A2 EP1327628A2 (fr) | 2003-07-16 |
EP1327628A3 EP1327628A3 (fr) | 2003-08-13 |
EP1327628B1 true EP1327628B1 (fr) | 2007-08-29 |
Family
ID=26996314
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP03006780A Expired - Lifetime EP1327628B1 (fr) | 1995-01-25 | 1996-01-25 | Lipidisation de molecules hydrophiles |
EP96903690A Expired - Lifetime EP0820285B1 (fr) | 1995-01-25 | 1996-01-25 | Procedes et compositions de lipidisation de molecules hydrophiles |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP96903690A Expired - Lifetime EP0820285B1 (fr) | 1995-01-25 | 1996-01-25 | Procedes et compositions de lipidisation de molecules hydrophiles |
Country Status (14)
Country | Link |
---|---|
US (4) | US5907030A (fr) |
EP (2) | EP1327628B1 (fr) |
JP (1) | JP3814294B2 (fr) |
KR (1) | KR100438268B1 (fr) |
CN (1) | CN1139385C (fr) |
AT (2) | ATE371643T1 (fr) |
AU (1) | AU699827B2 (fr) |
CA (1) | CA2211442A1 (fr) |
DE (2) | DE69628290T2 (fr) |
EA (1) | EA000584B1 (fr) |
ES (1) | ES2200051T3 (fr) |
FI (1) | FI973048A (fr) |
NO (1) | NO973403L (fr) |
WO (1) | WO1996022773A1 (fr) |
Families Citing this family (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5907030A (en) | 1995-01-25 | 1999-05-25 | University Of Southern California | Method and compositions for lipidization of hydrophilic molecules |
US7048906B2 (en) * | 1995-05-17 | 2006-05-23 | Cedars-Sinai Medical Center | Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions |
KR100691315B1 (ko) * | 1996-09-26 | 2007-03-12 | 유니버시티 오브 써던 캘리포니아 | 친수성 분자를 지질화시키기 위한 방법 및 조성물 |
GB9704519D0 (en) * | 1997-03-05 | 1997-04-23 | Smithkline Beecham Plc | Compounds |
US6093692A (en) * | 1997-09-25 | 2000-07-25 | The University Of Southern California | Method and compositions for lipidization of hydrophilic molecules |
TWI242000B (en) | 1998-12-10 | 2005-10-21 | Univ Southern California | Reversible aqueous pH sensitive lipidizing reagents, compositions and methods of use |
DE50013950D1 (de) * | 1999-05-07 | 2007-02-22 | Pharmasol Gmbh | Arzneistoffträger zur kontrollierten wirkstoffapplikation hergestellt aus lipidmatrix-arzneistoff-konjugaten (lak-partikel) |
EP2385124B1 (fr) | 1999-05-14 | 2013-09-11 | Arbor Vita Corporation | Peptides ou analogues de peptides pour moduler l'interaction entre und protéine PDZ et une protéine PL |
US6309633B1 (en) | 1999-06-19 | 2001-10-30 | Nobex Corporation | Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same |
CN1406131A (zh) * | 2000-12-25 | 2003-03-26 | 株式会社资生堂 | 活化交感神经的香料组合物 |
US7060675B2 (en) * | 2001-02-15 | 2006-06-13 | Nobex Corporation | Methods of treating diabetes mellitus |
US6828297B2 (en) * | 2001-06-04 | 2004-12-07 | Nobex Corporation | Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
US7713932B2 (en) * | 2001-06-04 | 2010-05-11 | Biocon Limited | Calcitonin drug-oligomer conjugates, and uses thereof |
US6828305B2 (en) * | 2001-06-04 | 2004-12-07 | Nobex Corporation | Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
US6713452B2 (en) | 2001-06-04 | 2004-03-30 | Nobex Corporation | Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
US7125568B2 (en) * | 2001-08-23 | 2006-10-24 | Sung Michael T | Lipophilic drug compositions |
US7166571B2 (en) * | 2001-09-07 | 2007-01-23 | Biocon Limited | Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same |
US7196059B2 (en) * | 2001-09-07 | 2007-03-27 | Biocon Limited | Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith |
US6913903B2 (en) * | 2001-09-07 | 2005-07-05 | Nobex Corporation | Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same |
US7312192B2 (en) * | 2001-09-07 | 2007-12-25 | Biocon Limited | Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same |
GB0121709D0 (en) * | 2001-09-07 | 2001-10-31 | Imp College Innovations Ltd | Food inhibition agent |
WO2003026591A2 (fr) | 2001-09-24 | 2003-04-03 | Imperial College Innovations Ltd. | Modification de comportement alimentaire |
GB0129121D0 (en) * | 2001-12-05 | 2002-01-23 | Ic Vec Ltd | Compound |
EP1474163A2 (fr) | 2002-01-10 | 2004-11-10 | Imperial College Innovations Limited | Modification des habitudes alimentaires |
US8058233B2 (en) * | 2002-01-10 | 2011-11-15 | Oregon Health And Science University | Modification of feeding behavior using PYY and GLP-1 |
US20080233181A1 (en) * | 2002-04-12 | 2008-09-25 | Nagy Jon O | Nanoparticle adjuvants for sub-unit vaccines |
US7285289B2 (en) * | 2002-04-12 | 2007-10-23 | Nagy Jon O | Nanoparticle vaccines |
GB0300571D0 (en) * | 2003-01-10 | 2003-02-12 | Imp College Innovations Ltd | Modification of feeding behaviour |
US20040151766A1 (en) * | 2003-01-30 | 2004-08-05 | Monahan Sean D. | Protein and peptide delivery to mammalian cells in vitro |
US20090074885A1 (en) * | 2003-09-08 | 2009-03-19 | Roche Madison Inc. | Reversible Hydrophobic Modification of Drugs for Improved Delivery to Cells |
US20050054612A1 (en) * | 2003-09-08 | 2005-03-10 | Monahan Sean D. | Delivery by labile hydrophobic modification of drugs |
WO2005061548A1 (fr) | 2003-12-23 | 2005-07-07 | Nono Inc. | Polypeptides pour la modulation de la liaison des proteines du canal de recepteur de potentiel transitoire et proteines associees au recepteur de potentiel transitoire |
US7282590B2 (en) * | 2004-02-12 | 2007-10-16 | The Research Foundation Of State University Of New York | Drug conjugates |
AU2005269753B2 (en) | 2004-07-19 | 2011-08-18 | Biocon Limited | Insulin-oligomer conjugates, formulations and uses thereof |
EP1695717A1 (fr) * | 2005-02-23 | 2006-08-30 | Ludwig-Maximilians-Universität | Transport de structures nano-et macromoléculaires dans le cytoplasme et le noyau des cellules |
GB0504857D0 (en) * | 2005-03-09 | 2005-04-13 | Imp College Innovations Ltd | Novel compounds and their effects on feeding behaviour |
GB0511986D0 (en) * | 2005-06-13 | 2005-07-20 | Imp College Innovations Ltd | Novel compounds and their effects on feeding behaviour |
PT1891105E (pt) | 2005-06-13 | 2012-06-27 | Imp Innovations Ltd | Análogos de oxintomodulina e seus efeitos sobre o comportamento da alimentação |
US8293900B2 (en) | 2005-09-29 | 2012-10-23 | Merck Sharp & Dohme Corp | Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators |
US20070232537A1 (en) * | 2005-12-19 | 2007-10-04 | Nastech Pharmaceutical Company Inc. | Intranasal pyy formulations with improved transmucosal pharmacokinetics |
AU2007300627B2 (en) | 2006-09-22 | 2012-02-16 | Merck Sharp & Dohme Corp. | Method of treatment using fatty acid synthesis inhibitors |
US8486384B2 (en) * | 2006-10-27 | 2013-07-16 | University Of Southern California | Lipidized interferon and methods of treating viral hepatitis |
TWI428346B (zh) | 2006-12-13 | 2014-03-01 | Imp Innovations Ltd | 新穎化合物及其等對進食行為影響 |
CA2682727C (fr) | 2007-04-02 | 2016-03-22 | Banyu Pharmaceutical Co., Ltd. | Derive d'indoledione |
US20100279930A1 (en) | 2007-07-09 | 2010-11-04 | Stephen Robert Bloom | Human pancreatic polypeptide (hpp) analogues and their effects on feeding behaviour |
PT2203181T (pt) * | 2007-10-16 | 2018-05-10 | Biocon Ltd | Uma composição farmacêutica sólida para administração por via oral e o seu processo de fabrico |
WO2009059984A2 (fr) * | 2007-11-06 | 2009-05-14 | F. Hoffmann-La Roche Ag | Hydrophobisation réversible pour une administration de médicament de premier passage |
GB0918579D0 (en) | 2009-10-22 | 2009-12-09 | Imp Innovations Ltd | Gadd45beta targeting agents |
GB201001333D0 (en) | 2010-01-27 | 2010-03-17 | Imp Innovations Ltd | Novel compounds and their effects on feeding behaviour |
GB201101459D0 (en) | 2011-01-27 | 2011-03-16 | Imp Innovations Ltd | Novel compounds and thier effects on fedding behaviour |
GB201107118D0 (en) | 2011-04-27 | 2011-06-08 | Imp Innovations Ltd | Method of diagnosis and prognosis |
WO2013004983A1 (fr) | 2011-07-04 | 2013-01-10 | Imperial Innovations Limited | Nouveaux composés et leurs effets sur le comportement alimentaire |
WO2015177572A1 (fr) | 2014-05-23 | 2015-11-26 | Imperial Innovations Limited | Analogues de peptide yy (pyy) |
GB201720187D0 (en) | 2017-12-04 | 2018-01-17 | Imperial Innovations Ltd | Novel Compounds |
GB201720188D0 (en) | 2017-12-04 | 2018-01-17 | Imperial Innovations Ltd | Analogues of PYY |
KR20210018267A (ko) | 2018-05-07 | 2021-02-17 | 알닐람 파마슈티칼스 인코포레이티드 | 간외 전달 |
GB201908424D0 (en) | 2019-06-12 | 2019-07-24 | Imp College Innovations Ltd | Novel compounds |
WO2022123271A1 (fr) | 2020-12-11 | 2022-06-16 | Imperial College Innovations Limited | Nouveaux composés |
EP4281034A1 (fr) | 2021-01-24 | 2023-11-29 | Forrest, Michael, David | Inhibiteurs d?utilisations cosmétiques et thérapeutiques d?atp synthase |
GB202302686D0 (en) | 2023-02-24 | 2023-04-12 | Imperial College Innovations Ltd | Novel compounds |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS63246382A (ja) * | 1987-04-02 | 1988-10-13 | Karupisu Shokuhin Kogyo Kk | ビオチニル試薬及びそれを用いるビオチニル化法 |
US5679643A (en) * | 1987-10-13 | 1997-10-21 | Terrapin Technologies, Inc. | Glutathione analogs and paralog panels comprising glutathione mimics |
US5599903A (en) * | 1992-04-03 | 1997-02-04 | Terrapin Technologies, Inc. | Glutathione analogs and paralog panels comprising glutathione mimics |
US5157123A (en) * | 1989-03-13 | 1992-10-20 | Georgetown University | S-(2-thiopyridyl)-l-cysteine, a heterobifunctional crosslinking reagent |
WO1991016067A1 (fr) * | 1990-04-23 | 1991-10-31 | Research Corporation Technologies, Inc. | Sources stables et solubles de tyrosine, de cysteine et de glutamine pour une alimentation parenterale totale |
US5629020A (en) * | 1994-04-22 | 1997-05-13 | Emisphere Technologies, Inc. | Modified amino acids for drug delivery |
JP3091270B2 (ja) * | 1990-09-28 | 2000-09-25 | 協和醗酵工業株式会社 | 美白化粧料 |
US5622929A (en) * | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
US5635380A (en) * | 1994-01-18 | 1997-06-03 | Vanderbilt University | Enhancement of nucleic acid transfer by coupling virus to nucleic acid via lipids |
US5907030A (en) | 1995-01-25 | 1999-05-25 | University Of Southern California | Method and compositions for lipidization of hydrophilic molecules |
WO1997049425A1 (fr) | 1996-06-25 | 1997-12-31 | Stichting Instituut Voor Dierhouderij En Diergezondheid | Vaccins comprenant des antigenes fixes sur leurs supports par des liaisons labiles |
-
1995
- 1995-09-05 US US08/524,362 patent/US5907030A/en not_active Expired - Fee Related
-
1996
- 1996-01-25 CN CNB961921285A patent/CN1139385C/zh not_active Expired - Fee Related
- 1996-01-25 AU AU47692/96A patent/AU699827B2/en not_active Ceased
- 1996-01-25 DE DE69628290T patent/DE69628290T2/de not_active Expired - Fee Related
- 1996-01-25 KR KR1019970705063A patent/KR100438268B1/ko not_active IP Right Cessation
- 1996-01-25 EP EP03006780A patent/EP1327628B1/fr not_active Expired - Lifetime
- 1996-01-25 AT AT03006780T patent/ATE371643T1/de not_active IP Right Cessation
- 1996-01-25 CA CA002211442A patent/CA2211442A1/fr not_active Abandoned
- 1996-01-25 AT AT96903690T patent/ATE240729T1/de not_active IP Right Cessation
- 1996-01-25 ES ES96903690T patent/ES2200051T3/es not_active Expired - Lifetime
- 1996-01-25 WO PCT/US1996/001052 patent/WO1996022773A1/fr active IP Right Grant
- 1996-01-25 JP JP52301596A patent/JP3814294B2/ja not_active Expired - Fee Related
- 1996-01-25 EP EP96903690A patent/EP0820285B1/fr not_active Expired - Lifetime
- 1996-01-25 DE DE69637229T patent/DE69637229T2/de not_active Expired - Lifetime
- 1996-01-25 EA EA199700143A patent/EA000584B1/ru not_active IP Right Cessation
- 1996-11-01 US US08/742,357 patent/US5936092A/en not_active Expired - Fee Related
-
1997
- 1997-07-18 FI FI973048A patent/FI973048A/fi unknown
- 1997-07-23 NO NO973403A patent/NO973403L/no not_active Application Discontinuation
-
1998
- 1998-07-22 US US09/120,118 patent/US6225445B1/en not_active Expired - Fee Related
-
2001
- 2001-05-01 US US09/845,153 patent/US7052704B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
WO1996022773A1 (fr) | 1996-08-01 |
CN1175902A (zh) | 1998-03-11 |
EA000584B1 (ru) | 1999-12-29 |
FI973048A (fi) | 1997-09-16 |
DE69637229D1 (de) | 2007-10-11 |
CN1139385C (zh) | 2004-02-25 |
EA199700143A1 (ru) | 1997-12-30 |
AU4769296A (en) | 1996-08-14 |
EP0820285B1 (fr) | 2003-05-21 |
KR19980701667A (ko) | 1998-06-25 |
JPH11500108A (ja) | 1999-01-06 |
FI973048A0 (fi) | 1997-07-18 |
EP0820285A4 (fr) | 1998-04-22 |
JP3814294B2 (ja) | 2006-08-23 |
NO973403L (no) | 1997-09-17 |
NO973403D0 (no) | 1997-07-23 |
US7052704B2 (en) | 2006-05-30 |
KR100438268B1 (ko) | 2004-09-04 |
ATE240729T1 (de) | 2003-06-15 |
EP1327628A2 (fr) | 2003-07-16 |
US20040054132A1 (en) | 2004-03-18 |
EP0820285A1 (fr) | 1998-01-28 |
US6225445B1 (en) | 2001-05-01 |
DE69637229T2 (de) | 2008-05-15 |
US5936092A (en) | 1999-08-10 |
AU699827B2 (en) | 1998-12-17 |
US5907030A (en) | 1999-05-25 |
EP1327628A3 (fr) | 2003-08-13 |
ATE371643T1 (de) | 2007-09-15 |
DE69628290T2 (de) | 2004-03-18 |
ES2200051T3 (es) | 2004-03-01 |
DE69628290D1 (de) | 2003-06-26 |
CA2211442A1 (fr) | 1996-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1327628B1 (fr) | Lipidisation de molecules hydrophiles | |
US6093692A (en) | Method and compositions for lipidization of hydrophilic molecules | |
JP4358521B2 (ja) | 細胞デリバリーのためのコンジュゲートおよび組成物 | |
US7553830B2 (en) | Compositions for the delivery of negatively charged molecules | |
US7491805B2 (en) | Conjugates and compositions for cellular delivery | |
US20030130186A1 (en) | Conjugates and compositions for cellular delivery | |
US20110124853A1 (en) | Conjugates and Compositions for Cellular Delivery | |
CA2238379A1 (fr) | Ligands servant a amplifier l'absorption cellulaire de biomolecules | |
EP3560517A2 (fr) | Conjugué de médicament aptamère et son utilisation | |
AU737865B2 (en) | Methods and compositions for lipidization of hydrophilic molecules | |
WO1998013007A9 (fr) | Procedes et compositions pour la lipidation de molecules hydrophile | |
KR20230088412A (ko) | 단일 치환된 동종 2가 링커를 포함하는 다중접합체 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
PUAL | Search report despatched |
Free format text: ORIGINAL CODE: 0009013 |
|
AC | Divisional application: reference to earlier application |
Ref document number: 0820285 Country of ref document: EP Kind code of ref document: P |
|
AK | Designated contracting states |
Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE |
|
AX | Request for extension of the european patent |
Extension state: LT LV SI |
|
AK | Designated contracting states |
Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE |
|
AX | Request for extension of the european patent |
Extension state: LT LV SI |
|
17P | Request for examination filed |
Effective date: 20040212 |
|
AKX | Designation fees paid |
Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE |
|
AXX | Extension fees paid |
Extension state: SI Payment date: 20040212 Extension state: LT Payment date: 20040212 Extension state: LV Payment date: 20040212 |
|
17Q | First examination report despatched |
Effective date: 20050407 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AC | Divisional application: reference to earlier application |
Ref document number: 0820285 Country of ref document: EP Kind code of ref document: P |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE |
|
AX | Request for extension of the european patent |
Extension state: LT LV SI |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REF | Corresponds to: |
Ref document number: 69637229 Country of ref document: DE Date of ref document: 20071011 Kind code of ref document: P |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20070829 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20071210 |
|
NLV1 | Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act | ||
LTIE | Lt: invalidation of european patent or patent extension |
Effective date: 20070829 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20070829 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: ISLER & PEDRAZZINI AG |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20070829 |
|
EN | Fr: translation not filed | ||
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20070829 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20071130 |
|
ET | Fr: translation filed | ||
REG | Reference to a national code |
Ref country code: FR Ref legal event code: EERR Free format text: CORRECTION DE BOPI 08/17 - BREVETS EUROPEENS DONT LA TRADUCTION N A PAS ETE REMISE A L INPI. IL Y A LIEU DE SUPPRIMER : LA MENTION DE LA NON-REMISE. LA REMISE DE LA TRADUCTION EST PUBLIEE DANS LE PRESENT BOPI. |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20080129 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20071129 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20080530 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20080131 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20080125 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20080131 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IE Payment date: 20110131 Year of fee payment: 16 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 20110131 Year of fee payment: 16 Ref country code: DE Payment date: 20110131 Year of fee payment: 16 Ref country code: FR Payment date: 20110211 Year of fee payment: 16 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20110120 Year of fee payment: 16 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20120125 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST Effective date: 20120928 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120125 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120131 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120131 Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120801 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 69637229 Country of ref document: DE Effective date: 20120801 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120131 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120125 |